Strategic Global Advisors LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 126.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,247 shares of the biopharmaceutical company’s stock after acquiring an additional 3,490 shares during the quarter. Strategic Global Advisors LLC’s holdings in Celgene were worth $811,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Neuberger Berman Group LLC increased its holdings in shares of Celgene by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC bought a new stake in shares of Celgene during the second quarter valued at approximately $3,616,000. Lincoln Capital Corp increased its holdings in shares of Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares in the last quarter. RiverPoint Capital Management LLC increased its holdings in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Celgene by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares in the last quarter. 80.17% of the stock is currently owned by institutional investors.
Several equities research analysts have recently commented on the company. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. Royal Bank Of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price target on shares of Celgene in a report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and a consensus target price of $139.57.
Celgene Corporation (NASDAQ CELG) traded up $0.56 during midday trading on Thursday, reaching $102.73. The company’s stock had a trading volume of 4,037,326 shares, compared to its average volume of 4,761,695. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The stock has a market cap of $80,747.23, a PE ratio of 16.02, a P/E/G ratio of 0.79 and a beta of 1.78.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the business posted $1.58 EPS. The business’s revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.
In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2017/12/07/celgene-corporation-celg-shares-bought-by-strategic-global-advisors-llc-updated-updated.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.